ImmuPharma PLC Financials
| IMM Stock | 1.57 0.02 1.26% |
Operating Margin 36.1472 | Return On Equity (1.11) |
ImmuPharma | Select Account or Indicator |
Understanding current and past ImmuPharma PLC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ImmuPharma PLC's financial statements are interrelated, with each one affecting the others. For example, an increase in ImmuPharma PLC's assets may result in an increase in income on the income statement.
Please note, the presentation of ImmuPharma PLC's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ImmuPharma PLC's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ImmuPharma PLC's management manipulating its earnings.
ImmuPharma PLC Stock Summary
ImmuPharma PLC competes with Samsung Electronics, Samsung Electronics, Hyundai, Toyota, and Reliance Industries. ImmuPharma PLC is entity of United Kingdom. It is traded as Stock on LSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | UK Stock View All |
| Exchange | London Exchange |
| ISIN | GB0033711010 |
| Business Address | 1 Bartholomew Close, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.immupharma.co.uk |
| Phone | 44 20 7206 2650 |
You should never invest in ImmuPharma PLC without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of ImmuPharma Stock, because this is throwing your money away. Analyzing the key information contained in ImmuPharma PLC's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
ImmuPharma PLC Key Financial Ratios
There are many critical financial ratios that ImmuPharma PLC's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that ImmuPharma PLC reports annually and quarterly.| Gross Profit | 118.35 K | ||||
| EBITDA | (3.03 M) | ||||
| Net Income | (2.92 M) | ||||
| Total Asset | 2.72 M | ||||
| Retained Earnings | (64.08 M) |
ImmuPharma PLC Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 5.8M | 10.9M | 6.0M | 4.0M | 2.7M | 2.6M | |
| Other Current Liab | 175.4K | 110.7K | 158.8K | 200.0K | 768.5K | 806.9K | |
| Net Debt | (1.3M) | (5.2M) | (1.6M) | (667.7K) | (208.5K) | (218.9K) | |
| Retained Earnings | (40.2M) | (46.0M) | (56.6M) | (61.1M) | (64.1M) | (60.9M) | |
| Cash | 1.4M | 5.9M | 1.6M | 667.8K | 208.5K | 198.1K | |
| Other Current Assets | 1.5M | 1.6M | 1.7M | 1.5M | 1.1M | 1.2M | |
| Total Liab | 531.9K | 1.3M | 1.6M | 1.5M | 1.7M | 1.7M | |
| Total Current Assets | 3.6M | 7.4M | 3.3M | 2.3M | 1.3M | 1.3M | |
| Common Stock | 16.7M | 25.0M | 28.5M | 29.0M | 29.8M | 31.3M | |
| Accounts Payable | 505.1K | 418.1K | 1.2M | 1.1M | 776.2K | 815.2K | |
| Net Receivables | 709.1K | 481.9K | 1.1M | 166.3K | 685.7K | 950.6K | |
| Short Term Debt | 26.8K | 641.8K | 700.0 | 111.0 | 99.9 | 94.91 | |
| Intangible Assets | 479.0K | 484.0K | 477.6K | 473.9K | 447.6K | 477.8K | |
| Net Tangible Assets | 5.2M | 9.6M | 3.9M | 2.5M | 2.8M | 5.2M | |
| Short Long Term Debt | 98.3K | 26.8K | 641.8K | 700.0 | 111.0 | 0.0 | |
| Capital Surpluse | 18.7M | 27.3M | 27.2M | 27.2M | 31.3M | 25.6M | |
| Net Invested Capital | 5.3M | 10.3M | 4.4M | 2.5M | 1.1M | 1.0M | |
| Net Working Capital | 3.0M | 6.2M | 1.8M | 887.6K | (321.9K) | (305.8K) | |
| Capital Stock | 16.7M | 25.0M | 28.5M | 29.0M | 29.8M | 26.2M |
ImmuPharma PLC Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 526.7K | 1.7M | 2.4M | 1.5M | 2.0K | 1.9K | |
| Operating Income | (6.3M) | (5.6M) | (6.6M) | (3.0M) | (3.1M) | (3.2M) | |
| Ebit | (6.2M) | (7.0M) | (8.8M) | (3.0M) | (3.1M) | (3.2M) | |
| Ebitda | (6.1M) | (6.8M) | (8.7M) | (2.9M) | (3.0M) | (3.2M) | |
| Income Before Tax | (6.7M) | (7.2M) | (8.9M) | (4.5M) | (3.4M) | (3.6M) | |
| Net Income | (6.1M) | (6.9M) | (8.2M) | (3.8M) | (2.9M) | (3.1M) | |
| Income Tax Expense | (620.8K) | (386.2K) | (766.8K) | (648.9K) | (497.1K) | (522.0K) | |
| Gross Profit | 77.9K | 126.7K | 118.4K | (117.6K) | (37.6K) | (35.7K) | |
| Research Development | 2.7M | 2.4M | 3.7M | 2.0M | 2.0M | 3.0M | |
| Tax Provision | (620.8K) | (386.2K) | (766.8K) | (648.9K) | (497.1K) | (522.0K) | |
| Net Interest Income | 1.7K | (1.7M) | (205.2K) | (1.4M) | 1.0K | 1.1K | |
| Interest Income | 5.7K | 41.1K | 651.0 | 28.6K | 3.0K | 2.9K |
ImmuPharma PLC Key Cash Accounts
Cash flow analysis captures how much money flows into and out of ImmuPharma PLC. It measures of how well ImmuPharma is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money ImmuPharma PLC brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money ImmuPharma had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what ImmuPharma PLC has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (3.5M) | 4.5M | (4.2M) | (981.6K) | (459.3K) | (436.4K) | |
| Free Cash Flow | (4.3M) | (3.7M) | (4.9M) | (2.5M) | (1.4M) | (1.4M) | |
| Other Non Cash Items | 219.6K | 405.2K | 391.6K | 833.2K | 909.9K | 955.4K | |
| Capital Expenditures | 107.1K | 360.3K | 50.9K | 106.0K | 2.0 | 1.9 | |
| Net Income | (6.3M) | (5.6M) | (6.6M) | (3.0M) | (2.9M) | (3.1M) | |
| End Period Cash Flow | 1.4M | 5.9M | 1.6M | 667.8K | 208.5K | 198.1K | |
| Depreciation | 88.0K | 171.0K | 114.1K | 117.6K | 37.6K | 35.7K | |
| Net Borrowings | (138.9K) | (89.2K) | 1.3M | (723.0K) | (831.4K) | (789.9K) | |
| Change To Netincome | 2.2M | 2.0M | 3.3M | 2.6M | 3.0M | 3.1M |
ImmuPharma Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ImmuPharma PLC's current stock value. Our valuation model uses many indicators to compare ImmuPharma PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImmuPharma PLC competition to find correlations between indicators driving ImmuPharma PLC's intrinsic value. More Info.ImmuPharma PLC is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmuPharma PLC's earnings, one of the primary drivers of an investment's value.ImmuPharma PLC Systematic Risk
ImmuPharma PLC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ImmuPharma PLC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on ImmuPharma PLC correlated with the market. If Beta is less than 0 ImmuPharma PLC generally moves in the opposite direction as compared to the market. If ImmuPharma PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ImmuPharma PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ImmuPharma PLC is generally in the same direction as the market. If Beta > 1 ImmuPharma PLC moves generally in the same direction as, but more than the movement of the benchmark.
ImmuPharma PLC Total Assets Over Time
ImmuPharma PLC November 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ImmuPharma PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ImmuPharma PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of ImmuPharma PLC based on widely used predictive technical indicators. In general, we focus on analyzing ImmuPharma Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ImmuPharma PLC's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.89 | |||
| Information Ratio | 0.0334 | |||
| Maximum Drawdown | 19.45 | |||
| Value At Risk | (5.06) | |||
| Potential Upside | 4.05 |
Complementary Tools for ImmuPharma Stock analysis
When running ImmuPharma PLC's price analysis, check to measure ImmuPharma PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuPharma PLC is operating at the current time. Most of ImmuPharma PLC's value examination focuses on studying past and present price action to predict the probability of ImmuPharma PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuPharma PLC's price. Additionally, you may evaluate how the addition of ImmuPharma PLC to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |